By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Merck Serono 

9, chemin des Mines
Case postale 54
Geneva    CH-1211  Switzerland
Phone: 41-22-414-3000 Fax: 41-22-731-2179



Company News
Kadimastem To Collaborate With Merck Serono To Advance Combined Efforts In Neurodegenerative Disease Area 8/4/2014 11:11:36 AM
MorphoSys AG And Merck Serono Enter Strategic Immuno-Oncology Collaboration 6/12/2014 7:45:10 AM
Merck Serono Announces FDA Win For Auxogyn, Inc.'s Early Embryo Viability Assessment (Eeva®) System 6/10/2014 4:43:56 PM
Merck Serono's President & CEO Belén Garijo Has Been Appointed To Board Of Directors Of L'Oréal 4/18/2014 9:09:57 AM
Auxogyn, Inc., Merck Serono Strike Eeva Test Pact 4/3/2014 7:10:56 AM
Merck's Consumer Health Division Breaks $1 Billion Barrier By Incorporating Brands From Merck Serono 3/6/2014 6:55:54 AM
Merck Serono Has Named Dr. John Orloff As Head Of Global Clinical Development 2/11/2014 1:44:40 PM
Week in Review: BeiGene Co.,Ltd Out-Licenses Novel Cancer Drug to Merck Serono 11/18/2013 10:29:30 AM
BeiGene Co.,Ltd, Merck Serono Add $232 Million+ R&D Deal To Growing Cancer Partnership 11/13/2013 6:46:05 AM
Merck Serono and Kadimastem Sign Memorandum of Understanding (MOU) on Drug Screening and Discovery for Neurodegenerative Diseases 11/4/2013 9:50:53 AM